Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Selective germline testing in multiple myeloma patients yields a six-fold increase in actionable cancer predisposition findings: Time for screening guidelines?

View Full Paper
Ask AI
Bookmark
Share

Authors

MRManuel Cobo del RosalSTSantiago Thibaud

Discussion

Loading...

Member takes

Overview

Analysis shows six-fold rise in pathogenic germline variants in multiple myeloma, suggesting new screening guidelines may be needed.

Key Points

  • Detection of actionable cancer variants increased significantly in multiple myeloma patients with targeted testing.
  • Among patients referred for testing, 40% of those with multiple myeloma carried pathogenic germline variants.
  • Germline testing utilized peripheral blood and saliva samples for genomic analysis across diverse racial backgrounds.
  • Results support the need for formal screening guidelines and indicate a risk-informed approach for referrals in hereditary cancer cases.

Cite This Study

Rosal et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db62https://doi.org/10.1182/blood-2025-2151
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pathogenic germline variants in a racially diverse real-world cohort of prostate cancer patients2025
  2. 2Performance and clinical utility of germline genetic testing criteria for predisposition to myeloid neoplasms in adults2025
  3. 3Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer2025
  4. 4Germline predisposition in pediatric malignancies: Insights from a retrospective study at Dana-Farber Cancer Institute2025
  5. 5Prevalence and impact of germline mutations in pancreatic ductal adenocarcinoma2026